Werewolf Therapeutics (HOWL) Price & Analysis

Compare

670 Followers

HOWL Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.60 - $4.18

Previous CloseN/A

Volume113.58K

Average Volume (3M)432.42K

Market Cap

$53.40M

Enterprise Value-$11.45M

Total Cash (Recent Filing)$92.04M

Total Debt (Recent Filing)$37.01M

Price to Earnings (P/E)―

Beta1.66

Next Earnings

Nov 06, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding44,873,646

10 Day Avg. Volume199,113

30 Day Avg. Volume432,422

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap-0.21

Enterprise Value/Revenue-10.01

Enterprise Value/Gross Profit-16.61

Enterprise Value/Ebitda0.22

Forecast

1Y Price Target

$8.20

Price Target Upside594.92% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Financial StabilityThe company ended the quarter with approximately $122.8 million in cash, expected to fund operations until 2Q26, indicating strong financial stability.

Investment PotentialThe partnership with Jazz Pharma and a cash position of $111MM make Werewolf an attractive investment opportunity.

Strategic ExpansionWerewolf's strategic expansion of their PREDATOR masking platform to CD3 T-cell engagers is supported by robust clinical validation and industry interest.

Bears Say

Clinical UncertaintyThere is uncertainty whether the outcomes of WTX-124’s monotherapy and combination trials will be robust enough to engage an investor base generally disinterested in novel cytokine programs.

Revenue ConcernsWerewolf reported no revenues for 4Q24 as expected, and R&D expenses were higher than estimated.

Strategic RisksIt is unlikely that the new strategic direction with TCE platform will result in significant appreciation for HOWL in the near-term due to its nascent development stage.

Werewolf Therapeutics News

Werewolf Therapeutics Adopts New Bylaws and Elects Directors

An update from Werewolf Therapeutics ( ($HOWL) ) is now available. On June 12, 2025, Werewolf Therapeutics, Inc....

2M ago

HOWL

Werewolf Therapeutics price target lowered to $9 from $10 at BofA

BofA lowered the firm’s price target on Werewolf Therapeutics (HOWL) to $9 from $10 and keeps a Buy...

2M ago

HOWL

Werewolf Therapeutics Receives Nasdaq Deficiency Notice

Werewolf Therapeutics ( ($HOWL) ) just unveiled an update. On May 13, 2025, Werewolf Therapeutics received a deficiency...

3M ago

HOWL

Strategic Expansion and Clinical Potential of Werewolf Therapeutics’ PREDATOR Platform Boosts Buy Rating

Leerink Partners analyst Daina Graybosch maintained a Buy rating on Werewolf Therapeutics (HOWL – Research Report) on May...

3M ago

HOWL

Werewolf Therapeutics price target lowered to $6 from $8 at Wedbush

Wedbush lowered the firm’s price target on Werewolf Therapeutics (HOWL) to $6 from $8 to adjust future financing...

3M ago

HOWL

Werewolf Therapeutics Reports Q1 2025 Financial Results

Werewolf Therapeutics, Inc. ( ($HOWL) ) has released its Q1 earnings. Here is a breakdown of the information...

3M ago

HOWL

Werewolf Therapeutics files $150M mixed securities shelf

16:14 EDT Werewolf Therapeutics (HOWL) files $150M mixed securities shelf Published first on TheFly – the ultimate source...

3M ago

HOWL

Werewolf Therapeutics reports Q1 EPS (40c), consensus (43c)

“Werewolf continues to build on our promising data and progress across our clinical-stage programs,” said Daniel J. Hicklin,...

3M ago

HOWL

Werewolf Therapeutics Announces Q1 2025 Financial Results

The latest update is out from Werewolf Therapeutics ( ($HOWL) ). On May 8, 2025, Werewolf Therapeutics announced...

3M ago

HOWL

Werewolf Therapeutics presents new preclinical data on IL-10 INDUKINE

Werewolf Therapeutics (HOWL) announced a poster presentation further characterizing its conditionally-activated IL-10 INDUKINE molecule, WTX-921, at IMMUNOLOGY2025, the...

3M ago

HOWL

Werewolf Therapeutics appoints Bloom as Chief Business Officer

Werewolf Therapeutics (HOWL) announced the appointment of Steven Bloom as Chief Business Officer. Bloom brings more than 35...

4M ago

HOWL

Promising Investment in Werewolf Therapeutics: Strong Financials and Strategic Partnerships Drive Growth Prospects

Werewolf Therapeutics (HOWL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today....

5M ago

HOWL

Unlocking Broader Therapeutic Potential: Andrew Fein’s Buy Rating on Werewolf Therapeutics

Andrew Fein, an analyst from H.C. Wainwright, reiterated the Buy rating on Werewolf Therapeutics (HOWL – Research Report)....

5M ago

HOWL

Werewolf Therapeutics Faces Geopolitical Risks Amid Changing Trade Policies with China

Werewolf Therapeutics, Inc. (HOWL) has disclosed a new risk, in the Capital Markets category. Werewolf Therapeutics, Inc. could...

5M ago

HOWL

HOWL FAQ

What was Werewolf Therapeutics’s price range in the past 12 months?

Werewolf Therapeutics lowest stock price was $0.59 and its highest was $4.18 in the past 12 months.

What is Werewolf Therapeutics’s market cap?

Werewolf Therapeutics’s market cap is $53.40M.

When is Werewolf Therapeutics’s upcoming earnings report date?

Werewolf Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 89 days.

How were Werewolf Therapeutics’s earnings last quarter?

Currently, no data Available

Is Werewolf Therapeutics overvalued?

According to Wall Street analysts Werewolf Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Werewolf Therapeutics pay dividends?

Werewolf Therapeutics does not currently pay dividends.

What is Werewolf Therapeutics’s EPS estimate?

Werewolf Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Werewolf Therapeutics have?

Werewolf Therapeutics has 44,873,646 shares outstanding.

What happened to Werewolf Therapeutics’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Werewolf Therapeutics?

Currently, no hedge funds are holding shares in HOWL

Werewolf Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-82.81%

Trailing 12-Months

Asset Growth

-39.62%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Werewolf Therapeutics

Werewolf Therapeutics, Inc. (HOWL) is a biopharmaceutical company focused on developing transformative cancer immunotherapies. The company operates in the biotechnology sector, specializing in the discovery, development, and commercialization of innovative therapeutics designed to harness the body's immune system to fight cancer. Werewolf's core products include a proprietary class of proinflammatory molecules called 'INDUKINE' molecules, which are engineered to stimulate the immune system selectively within the tumor microenvironment, aiming to improve efficacy and minimize systemic toxicity.

Werewolf Therapeutics (HOWL) Earnings & Revenues

Historic Earnings Reports

HOWL Stock 12 Month Forecast

Average Price Target

$8.20

▲(594.92% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","13":"$13","-1":"-$1","2.5":"$2.5","9.5":"$9.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2.5,6,9.5,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.16,1.9938461538461536,2.8276923076923075,3.661538461538461,4.495384615384615,5.329230769230769,6.163076923076923,6.996923076923077,7.8307692307692305,8.664615384615384,9.498461538461537,10.332307692307692,11.166153846153845,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.16,1.7015384615384614,2.2430769230769227,2.7846153846153845,3.3261538461538462,3.867692307692308,4.409230769230769,4.950769230769231,5.492307692307692,6.033846153846154,6.575384615384616,7.116923076923077,7.658461538461538,{"y":8.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.16,1.3784615384615384,1.596923076923077,1.8153846153846152,2.0338461538461536,2.252307692307692,2.4707692307692306,2.689230769230769,2.9076923076923076,3.126153846153846,3.344615384615384,3.563076923076923,3.781538461538461,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.02,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.17,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.35,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.3,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.16,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.48,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.48,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.87,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.87,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.2,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.05,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.16,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >